Drug Profile
Etoposide - SuperGen
Alternative Names: EtopoExtraLatest Information Update: 16 Jan 2022
Price :
$50
*
At a glance
- Originator SuperGen
- Class Antineoplastics; Tetrahydronaphthalenes
- Mechanism of Action Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Small cell lung cancer; Testicular cancer
Most Recent Events
- 30 Jul 2001 This compound is still in active development
- 08 May 1998 Preclinical development for Small cell lung cancer in USA (Parenteral)
- 08 May 1998 Preclinical development for Testicular cancer in USA (Parenteral)